NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CARCINOMA (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CARCINOMA (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CARCINOMA (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy showdown: new drug challenges chemo for lung cancer
Disease control OngoingThis study compared a new immunotherapy drug called durvalumab against standard chemotherapy as the first treatment for advanced non-small cell lung cancer. It involved 669 patients whose cancer had a specific biomarker (high PD-L1 expression) and had not received prior treatment…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Drug combo takes on standard chemo in major lung cancer trial
Disease control OngoingThis large, late-stage trial is comparing a new two-drug immunotherapy combination (durvalumab + tremelimumab) against standard chemotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination helps patients live longer. The study enrolled n…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New immune therapy battle against advanced lung cancer
Disease control OngoingThis large global study tested whether immunotherapy drugs (given alone or in combination) work better than standard chemotherapy as a first treatment for advanced non-small cell lung cancer. It involved over 1,100 patients whose cancer had spread and who had not received prior t…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC